Nortriptyline

Nortriptyline is a member of the tricyclic antidepressant class, a group named for the three-ring core of their chemical structure ^[1]. Within that class it is a secondary amine, meaning it lacks a methyl group present on related tertiary-amine tricyclics such as amitriptyline; in fact nortriptyline is the compound the body produces when it metabolizes amitriptyline in the liver ^[1]. This structural difference is not merely academic, because it shifts the drug's pharmacology toward a more noradrenergic profile and tends to make it somewhat better tolerated than its parent.

The drug was approved for medical use in the United States in 1964 and has long since become a low-cost generic taken by mouth ^[1]. Its original and principal indication is major depression, and clinicians sometimes guide dosing using blood-level monitoring, since a particular concentration range is associated with its antidepressant effect ^[1].

Beyond depression, nortriptyline is used off-label for a variety of conditions ^[1]. It is prescribed for chronic and neuropathic pain, for migraine prevention, and as an aid to smoking cessation, among other uses ^[1][3]. The evidence base varies by indication: while guidelines in Europe, the United Kingdom, and the United States have listed it as an option for neuropathic pain, a systematic review of the trials found only weak support for it and did not endorse it as a first-line treatment, noting that better-supported alternatives exist ^[2]. In chronic pain more broadly, tricyclics like nortriptyline remain a traditional part of treatment alongside newer antidepressant classes ^[3][4].

Like other tricyclics, nortriptyline acts on more than one neurotransmitter system and on several receptors, which accounts for both its effects and its characteristic side effects ^[3]. It is a prescription medicine, and its use requires attention to its safety profile.

That safety profile includes anticholinergic effects, a tendency to lower blood pressure on standing, and effects on the heart's electrical conduction ^[1]. A particularly important consideration is that tricyclic antidepressants have a narrow margin between therapeutic and toxic doses, which makes overdose dangerous, and like other antidepressants nortriptyline carries a warning about a possible increase in suicidal thoughts in people under twenty-five, especially early in treatment.

Tricyclics are the ones you respect. Overdose is genuinely dangerous because they are cardiotoxic (they disrupt heart rhythm), so the gap between a working dose and a harmful one is smaller than with modern antidepressants. Expect possible dry mouth, constipation, drowsiness, weight change, and orthostatic dizziness. Do not combine with MAO inhibitors (serotonin syndrome risk), and be careful with anything that stacks anticholinergic load or prolongs QT. This is a prescription drug; blood-level monitoring is standard for a reason.

The dangerous interaction is with monoamine oxidase inhibitors. Nortriptyline with phenelzine, tranylcypromine, selegiline or linezolid can produce hyperthermia, severe hypertension, seizures and death, and standard practice leaves two weeks between the two.

Nortriptyline is metabolized by CYP2D6, and inhibitors of that enzyme raise its levels several-fold. Fluoxetine, paroxetine, bupropion, duloxetine, terbinafine and quinidine are the common culprits; the result is anticholinergic toxicity, orthostatic blood pressure drops, delirium and widening of the QRS complex. People who are poor metabolizers by genotype start from the same place.

Beyond that, additive burdens do the damage. Other anticholinergic drugs bring constipation, urinary retention and confusion. Agents that prolong the QT interval or slow cardiac conduction, including class 1A antiarrhythmics, add to nortriptyline's own quinidine-like effect. Because tricyclics block the noradrenaline transporter, the pressor response to injected epinephrine or norepinephrine is exaggerated, which is why dental and surgical teams ask about them.

Checking a whole stack? Run it through interactions + stacks.

Nortriptyline is a secondary-amine tricyclic antidepressant that arose from the first generation of tricyclics developed in the late 1950s and early 1960s; it is the principal active metabolite of amitriptyline. It was introduced in the United States in 1964 and marketed under names including Aventyl and Pamelor. Nortriptyline became an early landmark in therapeutic drug monitoring after Scandinavian researchers, notably Marie Asberg and colleagues in the early 1970s, described an unusual curvilinear relationship between its plasma concentration and antidepressant response; a therapeutic window outside which efficacy declined. Over subsequent decades its use broadened well beyond depression to neuropathic pain, migraine prophylaxis, and smoking cessation. It remains an inexpensive generic and is counted among widely used long-established medicines.

Nortriptyline has aged into a respected, versatile workhorse. Although the tricyclics have largely been displaced as first-line antidepressants by newer agents, nortriptyline is often singled out as the best tolerated of its class, particularly in older adults, owing to its relative selectivity and comparatively mild anticholinergic and blood-pressure effects. It has earned a durable second life in the treatment of neuropathic pain and the prevention of migraine, where low doses can help, and it has even shown value as an aid to quitting smoking. Its well-characterized therapeutic plasma window makes its dosing unusually rational and monitorable. The honest limits are those of the class; overdose can be dangerous to the heart, and side effects such as dry mouth and drowsiness are common, but as an inexpensive, well-understood generic it retains real clinical value.